Cargando…
Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy
Published data suggest that immunotherapy plays a role even in patients with very advanced tumours. We investigated the immune profile of end-stage cancer patients treated with immunotherapy to identify changes induced by treatment. Breast, colon, renal and prostate cancer patients were eligible. Tr...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999072/ https://www.ncbi.nlm.nih.gov/pubmed/33800511 http://dx.doi.org/10.3390/vaccines9030235 |
_version_ | 1783670698696245248 |
---|---|
author | Merlano, Marco Carlo Abbona, Andrea Paccagnella, Matteo Falletta, Antonella Granetto, Cristina Ricci, Vincenzo Fea, Elena Denaro, Nerina Ruatta, Fiorella Merlotti, Anna Bertetto, Oscar Crosetto, Nicola Galizia, Danilo Basiricò, Marco Gammaitoni, Loretta Sangiolo, Dario Aglietta, Massimo Garrone, Ornella |
author_facet | Merlano, Marco Carlo Abbona, Andrea Paccagnella, Matteo Falletta, Antonella Granetto, Cristina Ricci, Vincenzo Fea, Elena Denaro, Nerina Ruatta, Fiorella Merlotti, Anna Bertetto, Oscar Crosetto, Nicola Galizia, Danilo Basiricò, Marco Gammaitoni, Loretta Sangiolo, Dario Aglietta, Massimo Garrone, Ornella |
author_sort | Merlano, Marco Carlo |
collection | PubMed |
description | Published data suggest that immunotherapy plays a role even in patients with very advanced tumours. We investigated the immune profile of end-stage cancer patients treated with immunotherapy to identify changes induced by treatment. Breast, colon, renal and prostate cancer patients were eligible. Treatment consisted of metronomic cyclophosphamide, low-dose interleukin-2 (IL-2) and a single radiation shot. A panel of 16 cytokines was assessed using automated ELISA before treatment (T0), after radiation (RT; T1), at cycle 2 (T2) and at disease progression (TPD). Receiving operating characteristic (ROC) analysis was used to identify cytokine cut-off related to overall survival (OS). Principal component analysis (PCA) was used to identify the immune profile correlating better with OS and progression-free survival. Twenty-three patients were enrolled. High IL-2, low IL-8 and CCL-2 correlated with OS. The PCA identified a cluster of patients, with high IL-2, IL-12 and IFN-γ levels at T0 having longer PFS and OS. In all cohorts, IL-2 and IL-5 increased from T0 to T2; a higher CCL-4 level compared to T2 and a higher IL-8 level compared to T0 were found at TPD. The progressive increase of the IL-10 level during treatment negatively correlated with OS. Our data suggested that baseline cytokine levels may predict patients’ outcome and that the treatment may affect their kinetic even in end-stage patients. Cytokine profiling of end-stage patients might offer a tool for medical decisions (EUDRACT: 2016-000578-39). |
format | Online Article Text |
id | pubmed-7999072 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79990722021-03-28 Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy Merlano, Marco Carlo Abbona, Andrea Paccagnella, Matteo Falletta, Antonella Granetto, Cristina Ricci, Vincenzo Fea, Elena Denaro, Nerina Ruatta, Fiorella Merlotti, Anna Bertetto, Oscar Crosetto, Nicola Galizia, Danilo Basiricò, Marco Gammaitoni, Loretta Sangiolo, Dario Aglietta, Massimo Garrone, Ornella Vaccines (Basel) Article Published data suggest that immunotherapy plays a role even in patients with very advanced tumours. We investigated the immune profile of end-stage cancer patients treated with immunotherapy to identify changes induced by treatment. Breast, colon, renal and prostate cancer patients were eligible. Treatment consisted of metronomic cyclophosphamide, low-dose interleukin-2 (IL-2) and a single radiation shot. A panel of 16 cytokines was assessed using automated ELISA before treatment (T0), after radiation (RT; T1), at cycle 2 (T2) and at disease progression (TPD). Receiving operating characteristic (ROC) analysis was used to identify cytokine cut-off related to overall survival (OS). Principal component analysis (PCA) was used to identify the immune profile correlating better with OS and progression-free survival. Twenty-three patients were enrolled. High IL-2, low IL-8 and CCL-2 correlated with OS. The PCA identified a cluster of patients, with high IL-2, IL-12 and IFN-γ levels at T0 having longer PFS and OS. In all cohorts, IL-2 and IL-5 increased from T0 to T2; a higher CCL-4 level compared to T2 and a higher IL-8 level compared to T0 were found at TPD. The progressive increase of the IL-10 level during treatment negatively correlated with OS. Our data suggested that baseline cytokine levels may predict patients’ outcome and that the treatment may affect their kinetic even in end-stage patients. Cytokine profiling of end-stage patients might offer a tool for medical decisions (EUDRACT: 2016-000578-39). MDPI 2021-03-08 /pmc/articles/PMC7999072/ /pubmed/33800511 http://dx.doi.org/10.3390/vaccines9030235 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Article Merlano, Marco Carlo Abbona, Andrea Paccagnella, Matteo Falletta, Antonella Granetto, Cristina Ricci, Vincenzo Fea, Elena Denaro, Nerina Ruatta, Fiorella Merlotti, Anna Bertetto, Oscar Crosetto, Nicola Galizia, Danilo Basiricò, Marco Gammaitoni, Loretta Sangiolo, Dario Aglietta, Massimo Garrone, Ornella Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy |
title | Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy |
title_full | Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy |
title_fullStr | Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy |
title_full_unstemmed | Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy |
title_short | Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy |
title_sort | cytokine profiling of end stage cancer patients treated with immunotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999072/ https://www.ncbi.nlm.nih.gov/pubmed/33800511 http://dx.doi.org/10.3390/vaccines9030235 |
work_keys_str_mv | AT merlanomarcocarlo cytokineprofilingofendstagecancerpatientstreatedwithimmunotherapy AT abbonaandrea cytokineprofilingofendstagecancerpatientstreatedwithimmunotherapy AT paccagnellamatteo cytokineprofilingofendstagecancerpatientstreatedwithimmunotherapy AT fallettaantonella cytokineprofilingofendstagecancerpatientstreatedwithimmunotherapy AT granettocristina cytokineprofilingofendstagecancerpatientstreatedwithimmunotherapy AT riccivincenzo cytokineprofilingofendstagecancerpatientstreatedwithimmunotherapy AT feaelena cytokineprofilingofendstagecancerpatientstreatedwithimmunotherapy AT denaronerina cytokineprofilingofendstagecancerpatientstreatedwithimmunotherapy AT ruattafiorella cytokineprofilingofendstagecancerpatientstreatedwithimmunotherapy AT merlottianna cytokineprofilingofendstagecancerpatientstreatedwithimmunotherapy AT bertettooscar cytokineprofilingofendstagecancerpatientstreatedwithimmunotherapy AT crosettonicola cytokineprofilingofendstagecancerpatientstreatedwithimmunotherapy AT galiziadanilo cytokineprofilingofendstagecancerpatientstreatedwithimmunotherapy AT basiricomarco cytokineprofilingofendstagecancerpatientstreatedwithimmunotherapy AT gammaitoniloretta cytokineprofilingofendstagecancerpatientstreatedwithimmunotherapy AT sangiolodario cytokineprofilingofendstagecancerpatientstreatedwithimmunotherapy AT agliettamassimo cytokineprofilingofendstagecancerpatientstreatedwithimmunotherapy AT garroneornella cytokineprofilingofendstagecancerpatientstreatedwithimmunotherapy |